Crescent Biopharma Reports Q3 2026 Results, $289.4 Million in Cash

Crescent Biopharma reported a third-quarter 2026 net loss of $37.7 million, compared with $24.6 million a year earlier, as it continued advancing its oncology pipeline. Cash and cash equivalents totaled $289.4 million at September 30, 2026, which the company expects to support operations into the s…